Halozyme and Skye partner on obesity drug delivery technology Jan 5, 2026 07:01AM
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity Jan 5, 2026 07:00AM
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights Aug 9, 2024 05:59PM
CEO Presenting on the Emerging Growth Conference on June 9. Register here Jun 7, 2021 07:00AM